Rafael V. V.
- Country
- Spain
- Department
- Oncology
Research Overview
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
- Evaluation of Trastuzumab Deruxtecan in Combination with Anti-Cancer Agents in HER2-Positive Metastatic Breast Cancer with Brain Metastases
- Phase 3 Randomized Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in Triple-Negative Breast Cancer Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 96 of 320 partner sites.
Specializations
Breast Cancer Treatment Innovation
The investigator specializes in developing targeted therapies for HER2-positive metastatic breast cancer, with particular attention to patients with brain metastases. Their research encompasses innovative combination treatments using trastuzumab deruxtecan (T-DXd) alongside other anticancer agents.
- Advanced Metastatic Breast Cancer
- Brain Metastases Management
- Combination Therapy Approaches
Targeted Molecular Therapies
The investigator focuses on treating ESR1-mutated metastatic breast cancer through specialized molecular targeting. Their work involves the evaluation of novel therapeutic combinations including CDK4/6 inhibitors and investigating their efficacy compared to conventional treatments.
- ESR1 Mutation Detection
- Hormone Receptor-Positive Disease
- Advanced Treatment Strategies
Early-Stage Breast Cancer
The investigator studies adjuvant therapy optimization for hormone receptor-positive/HER2-negative early breast cancer. Their research evaluates the effectiveness of combining endocrine therapy with palbociclib to improve patient outcomes.
- Adjuvant Therapy Innovation
- Long-term Disease Management
- Early Intervention Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.